Showing results (511-520 of 1,824) with videos related to

Sort By:
Pageof 183
Signal Transduction and Targeted Therapy|May 18, 2019
Structural basis for the acetylation of histone H3K9 and H3K27 mediated by the histone chaperone Vps75 in Pneumocystis cariniiYiping Chen, Yang Zhang, Hui Ye, et al.
Signal Transduction and Targeted Therapy|April 24, 2018
Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survivalEnrique Rozengurt, James Sinnett-Smith, Guido Eibl
Signal Transduction and Targeted Therapy|April 24, 2018
Erratum: Author Correction: Angiotensin type 2 receptor activation promotes browning of white adipose tissue and brown adipogenesisAung Than, Shaohai Xu, Ru Li, et al.
Signal Transduction and Targeted Therapy|September 26, 2021
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gammaJiejie Geng, Liang Chen, Yufeng Yuan, et al.
Signal Transduction and Targeted Therapy|July 21, 2022
Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donorKeith Al-Hasani, Ishant Khurana, Lina Mariana, et al.
Signal Transduction and Targeted Therapy|July 26, 2022
Functional isolation, culture and cryopreservation of adult human primary cardiomyocytesBingying Zhou, Xun Shi, Xiaoli Tang, et al.
Signal Transduction and Targeted Therapy|April 28, 2022
Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridineChen Xue, Qingfei Chu, Qiuxian Zheng, et al.
Signal Transduction and Targeted Therapy|February 15, 2022
Therapeutic peptides: current applications and future directionsLei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|March 11, 2022
Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomasYan-Xia Wang, Haibo Wu, Yong Ren, et al.
Pageof 183